Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Our ability to fund our projects enables us to execute and deliver on our mission.
Data Provided by Refinitiv. Minimum 15 minutes delayed.

-
June 1, 2022
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 1, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date: Thursday, June 9 at 9:00 a.m.
-
May 5, 2022
Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--May 5, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and first quarter 2022 financial results.
-
May 2, 2022
BRISBANE, Calif. --(BUSINESS WIRE)--May 2, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25 th ASGCT Annual Meeting being held May
-
April 28, 2022
BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022 .
Filing date | Form | Description | Filing Group | View |
---|---|---|---|---|
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML | |
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML | |
4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
View HTML |
-
Jul 12, 2022 at 2:45 PM EDT
-
Jun 9, 2022 at 9:00 AM EDT
-
May 24, 2022 at 7:00 AM EDT